References
- Weiden P L, Flournoy N, Thomas E D. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. N Engl J Med 1979; 800: 1068
- Weiden P L, Sullivan K M, Flournoy N, Storb R, Thomas E D. Antileukemic effect of chronic graft-versus-host disease: Contribution to improved survival after allogeneic marrow transplantation. N Engl J Med 1981; 304: 1529
- Horowitz M M, Gale R P, Sondel P M. . Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990; 75: 555
- Slavin S, Strober S. Spontaneous murine B-cell leukemia. Nature 1978; 272: 624
- Slavin S, Weiss L, Morrecki S: B-cell leukemia (BCL1), a murine model of chronic lymphocytic leukemia. 1. Ultrastructural, cell membrane and cytogenetic characteristics. Cancer Res 1981; 441: 4162
- Slavin S, Weiss L, Morecki S, Weigensberg M. Eradication of murine leukemia with histoincompatible marrow grafts in mice conditioned with total lymphoid irradiation (TLI). Cancer Immunol Immunother 1981; 11: 155
- Weiss L, Morecki S, Vitetta E S, Slavin S. Suppression and elimination of BCL1 leukemia by allogeneic bone marrow transplantation. J Immunol 1981; 130: 2452
- Cobbold S, Martin G, Waldmann H. Monoclonal antibodies for the prevention of graft-versus-host disease and marrow graft rejection: The depletion of T-cell subsets in vitro and in vivo. Transplantation 1986; 42: 239
- Truitt R L, Shih C-Y, LeFever A V. Characterization of alloimmunization-induced T lymphocytes reactive against AKR leukemia in vitro and correlation with graft-vs-leukemia activity in vivo. J Immunol 1983; 131: 2050
- O'Kunewick J P, Kociban D L, Buffo M J, Young C K. Graft-versus-host disease and graft-versus-leukemia in experimental systems. Bone Marrow Transplantation, SJ Baum, GW Santos, F. Takaku. Springer-Verlag, New York 1987; 1
- Barrett A J, Horowitz M M, Gale R P. Marrow transplantation for acute lymphoblastic leukemia: Factors affecting relapse and survival. Blood 1989; 74: 862
- Goldman J M, Gale R P, Horowitz M M. Bone marrow transplantation for chronic myelogeneous leukemia in chronic phase; increased risk for relapse associated with T-cell depletion. Ann Intern Med 1988; 108: 806
- Rosenberg S A. The development of new immunotherapies for the treatment of cancer using interleukin-2. Ann Surg 1988; 208: 121
- Slavin S, Ackerstein A, Weiss L. Adoptive immunotherapy in conjunction with bone marrow transplantation–amplification of natural host defence mechanisms against cancer by recombinant IL2. Nat Immun Cell Growth Reg 1988; 7: 180
- Ackerstein A, Kedar E, Slavin S. Use of recombinant human interleukin-2 in conjunction with syngeneic bone marrow transplantation in mice as a model for control of minimal residual disease in malignant hematological disorders. Blood, in press